Muscle Invasive Urothelial Carcinoma
Advertisement
The RaDar assay tracks up to 48 tumor-specific variants in cell-free DNA in a cancer patient’s blood plasma.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Matthew Galsky, MD, contextualizes HCRN GU 16-257 as a potential game-changer for bladder sparing in patients with MIBC.
IAC-RT may be a useful and tolerable treatment option for patients with MIBC who are unfit for radical cystectomy.
Researchers examined the impact of care fragmentation on patients receiving neoadjuvant chemotherapy and radical cystectomy.
DLRS-based MLP was clinical useful in distinguishing non-muscle-invasive bladder cancer from muscle-invasive bladder cancer.
MRE11 “has been identified as a candidate predictive biomarker," as higher levels are associated with more ...
At a 36-month follow-up, the EFS and OS rates were 74.4% and 83.8% in the ITT group, and 92% of patients underwent RC.
ddMVACx6 was demonstrated to improve progression-free survival compared with GCx4 for muscle-invasive disease.
The data, published in Clinical Genitourinary Cancer, showed a lack of benefit of adjuvant ICIs across multiple subgroups.
A trial utilized atezolizumab, a monoclonal antibody directed at the PD-L1 protein, in patients with MIBC.
Clinical trial results showed that immunotherapy drug nivolumab helps reduce cancer recurrence in bladder cancer patients.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726